A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The aim of this prospective study was to evaluate the activity, safety and the duration of
the response of low dose rituximab associated with standard oral prednisone as first line
therapy in newly diagnosed warm autoimmune hemolytic anemia and cold hemagglutinin disease,
and as second line therapy in warm autoimmune hemolytic anemia relapsed after standard oral
prednisone. Further aim was to correlate the clinical response to biological parameters
(cytokine and anti-erythrocyte antibody production in cultures).
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico